Medicus Pharma Narrows Focus on 200µg Dose After SkinJect Phase 2 Clarification
Event summary
- Medicus Pharma clarified Phase 2 results for SkinJect, focusing on the 200µg dose cohort which showed the highest activity.
- The 200µg dose demonstrated 73% clinical clearance and 40% histological response at Day 57.
- The company plans to advance the 200µg dose regimen in registrational studies and align with FDA guidance.
- The device-only arm data will be treated as supportive, not pivotal, in future development.
- Medicus aims to accelerate partnering discussions following the Phase 2 results.
The big picture
Medicus Pharma's clarification of the SkinJect Phase 2 data underscores the company's strategic shift towards the 200µg dose, positioning it for potential regulatory approval and commercialization. This move aligns with broader industry trends towards non-surgical treatments for skin cancer, particularly in addressing the $2 billion market opportunity for non-melanoma skin diseases. The focus on the 200µg dose cohort reflects a targeted approach to maximize therapeutic efficacy and streamline the path to market.
What we're watching
- Regulatory Pathway
- Whether the FDA will accept the 200µg dose data as sufficient for a registrational study.
- Partnering Strategy
- The pace at which Medicus can secure strategic partnerships to advance SkinJect.
- Clinical Development
- How the refined study design and endpoints will impact the success of future SkinJect trials.
Related topics